Obesity drug developer Ambrosia Biosciences has closed an impressive $100 million second round, garnering the funds it needs to advance its oral GLP-1 agonist into clinical testing.

肥胖症药物开发商Ambrosia Biosciences完成了令人瞩目的1亿美元第二轮融资，获得了将其口服GLP-1激动剂推进到临床试验所需的资金。

The Series B was announced just before Eli Lilly won FDA approval for its oral GLP-1 drug

B轮融资刚刚在礼来公司获得FDA对其口服GLP-1药物的批准前宣布。

Foundayo

基金会

(orforglipron), which will now compete with Novo Nordisk's first-mover

（orforglipron），现在将与诺和诺德的先行者竞争

Wegovy

韦哥威

(semaglutide) pill in the weight-loss market.

（司美鲁肽）减肥市场的药丸。

Boulder, Colorado-based Ambrosia is developing a portfolio of small-molecule candidates for cardiometabolic diseases like obesity and diabetes, and also has agonist programmes targeting GIP and amylin. The proceeds of the round will support the development of those as well as initial clinical testing of its GLP-1 candidate.

总部位于科罗拉多州博尔德的Ambrosia公司正在开发一系列针对肥胖和糖尿病等心脏代谢疾病的小分子候选药物，同时还有针对GIP和淀粉素的激动剂项目。此轮融资将用于支持这些项目的开发，以及其GLP-1候选药物的初步临床试验。

The company maintains that its drug delivery approach, focused on structural biology and computational chemistry, will deliver ' best-in-class…molecules with differentiated pharmacology to support both standalone therapies and strategic combinations.'.

公司坚持认为，其专注于结构生物学和计算化学的药物传递方法将提供“同类最佳……具有差异化药理学的分子，以支持独立疗法和战略组合。”

The financing was co-led by new investors Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital. Existing backers BVF Partners and Boulder Ventures also joined in, alongside new supporters Janus Henderson Investors, Samsara BioCapital, and an unnamed institutional investor.

本轮融资由新投资者蓝猫头鹰医疗机会基金、红英里和深轨资本共同领投。现有支持者BVF合伙人和博尔德创投也参与其中，同时还有新支持者骏利亨德森投资、桑萨拉生物资本和一位未具名的机构投资者加入。

Other recent private rounds

其他最近的私人回合

US-Chinese biotech

美国-中国生物技术

Pinnacle Medicines

巅峰医药

, a specialist in oral peptide therapeutics, raised $89 million in a Series B co-led by LAV and Foresite Capital, with buy-in from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital, and existing investors including OrbiMed.

，一家专注于口腔肽治疗的公司，在由礼来亚洲基金（LAV）和远见资本（Foresite Capital）共同领投的B轮融资中筹集了8900万美元，参与投资的还包括泉资本（Quan Capital）、翰康资本（Hankang Capital）、RA资本管理（RA Capital Management）、逻格斯资本（Logos Capital）以及包括奥博资本（OrbiMed）在内的现有投资者。

The company is developing what it describes as a ' new generation' of peptide medicines designed to deliver biologic-level safety and efficacy with the convenience of oral dosing. All of its drug candidates are still in the early stages of development, and its covers indications including asthma and chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, atopic dermatitis, and cardiometabolic disorders like obesity..

公司正在开发被其称为“新一代”的肽类药物，旨在提供生物制品级别的安全性和有效性，同时具备口服给药的便利性。其所有候选药物仍处于开发的早期阶段，适应症覆盖包括哮喘和慢性阻塞性肺病（COPD）、炎症性肠病、特应性皮炎以及肥胖等心代谢疾病。

Cambridge, UK-based

英国剑桥郡

Immutrin

伊穆特林

completed a series A, raising £65 million ($87 million) to fund the development of its antibody-based therapy for ATTR cardiomyopathy, a serious and often fatal form of amyloidosis, through to proof-of-concept. The drug binds to amyloid fibrils and is engineered to deplete amyloid deposits in tissue via a targeted and coordinated immune response, according to the company..

完成了A轮融资，筹集了6500万英镑（8700万美元），以资助其基于抗体的ATTR心肌病治疗药物的开发，直至概念验证阶段。ATTR心肌病是一种严重且常常致命的淀粉样变性疾病。该药物能够结合淀粉样纤维，并通过靶向和协调的免疫反应来清除组织中的淀粉样沉积物，公司表示。

The round was led by Frazier Life Sciences with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures.

本轮融资由弗雷泽生命科学公司领投，F-Prime、启明创投、SR One 以及创始投资者剑桥创新资本和剑桥企业风险投资公司参与。

Finally, New York's

最后，纽约的

Gilgamesh Pharma

吉尔伽美什制药

– a spinout company formed when AbbVie

– 一家从艾伯维分拆出来的公司

bought

购买

Gilgamesh Pharmaceuticals and its psychedelic drug bretisilocin for major depressive disorder (MDD) for $1.2 billion last year – has closed a $60 million Series A in its first raise as a new company.

去年，吉尔伽美什制药公司及其用于重度抑郁症（MDD）的迷幻药物布雷替西洛辛达成了12亿美元的交易——该公司现已完成了作为新公司的首轮融资，A轮融资额达6000万美元。

Its main focus now is blixeprodil (GM-1020), a non-competitive glutamate NMDA receptor antagonist for MDD that recently had positive results in a phase 2 trial. The new funding will fund further development of that drug and also support the start of phase 1 trials of an ibogaine analogue, κ-opioid receptor (KOR) agonist GM-3009, with potential as a treatment for opioid use disorder.

其当前的主要焦点是布利克塞匹啶（GM-1020），这是一种非竞争性谷氨酸NMDA受体拮抗剂，用于治疗重度抑郁症（MDD），最近在二期试验中取得了积极结果。新的资金将用于进一步开发该药物，并支持伊博加因类似物、κ-阿片受体（KOR）激动剂GM-3009的一期试验启动，该药物有潜力成为治疗阿片类药物使用障碍的疗法。

The Series A financing was led by Satori Neuro, alongside participation from new and existing institutional investors, including Prime Movers Lab..

A轮融资由Satori Neuro领投，新投资者和现有机构投资者共同参与，包括Prime Movers Lab。

Image by

图片由

Mohamed Hassan

穆罕默德·哈桑

from

从

Pixabay

Pixabay